Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

It will be sold under the brand name Journavx (JOUR-nah-vix) to treat moderate to severe, acute, short-term pain in adults. It was approved Jan. 30, but is not available for prescription yet.

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U ...

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...

The oral NaV1.8 inhibitor has been cleared under the Journavx brand name with a broad label to treat adults with moderate-to-severe acute pain - for example, after trauma or surgery - and works by ...

If that is a signal of reduced efficacy in chronic pain it could be a drag on Journavx peak sales potential, as that is a much larger market opportunity than acute pain. Vertex said it intended to ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...